Compound class:
Synthetic organic
Comment: This compound was designed at Mirati Therapeutics, to selectively inhibit PI3Kα with the H1047R mutation that is prevalent in select solid tumours [1]. This approach spares the activity of wild type PI3Kα that is required for normal cellular functions.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Induces tumour regression in the mouse HCC1954 xenograft model. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|